论文部分内容阅读
目的:探讨不同恶病质状态癌痛患者疼痛情况及应用羟考酮的不良反应。方法:回顾性分析2018年1月至2020年1月在山东省泰安市肿瘤防治院就诊的136例不同恶病质状态癌痛患者资料，其中，中重度癌痛108例，使用羟考酮缓释片治疗84例。比较恶病质前期、恶病质期及恶病质难治期患者数字评分法（NRS）疼痛分级、止痛药物剂量、不良反应、中枢神经系统症状差异及其与羟考酮剂量的关系。结果:恶病质期和恶病质难治期癌痛患者NRS评分、应用高剂量阿片类药物者比例、重度癌痛发生率、难治性癌痛发生率均高于恶病质前期患者[（5.82±1.69）分、（6.60±1.59）分比（4.19±1.66）分，11.76%（4/34）、20.00%（7/35）比2.99%（2/67），26.47%（9/34）、62.86%（22/35）比8.96 %（6/67），17.65%（6/34）、28.57%（10/35）比5.97 %（4/67）；均n P<0.05]；恶病质期及恶病质难治期患者中枢神经系统症状发生率高于恶病质前期患者[32.14%（9/28）、48.00%（12/25）比12.90%（4/31），n P0.05）。n 结论:恶病质与恶病质难治期癌痛患者疼痛程度高于恶病质前期患者；患者中枢神经系统症状的发生可能受恶病质分期影响，与羟考酮剂量无关。“,”Objective:To investigate the pain situation and the adverse effects of oxycodone in cancer pain patients with different cachexia status.Methods:The data of 136 cancer pain patients with different cachexia status treated in Tai'an Tumor Prevention and Treatment Hospital of Shandong Province from January 2018 to January 2020 were retrospectively analyzed, including 108 patients with moderate to severe cancer pain and 84 patients receiving oxycodone. The pain degree evaluated by numerical rating scale (NRS) method, analgesic dosage, adverse reactions and symptom differences of the central nervous system (CNS) and their relationship with oxycodone dosage were compared in patients with different cachectic stages including pre-cachexia stage, cachexia stage and cachexia refractory stage.Results:NRS score, proportion of patients using high-dose opioids, severity cancer pain rate of patients and refractory cancer pain rate of patients in cachexia stage and refractory stage were higher than those of patients in pre-cachexia stage [(5.82±1.69) scores, (6.60±1.59) scores vs. (4.19±1.66) scores; 11.76% (4/34), 20.00% (7/35) vs. 2.99% (2/67); 26.47% (9/34), 62.86% (22/35) vs. 8.96% (6/67); 17.65% (6/34), 28.57% (10/35) vs. 5.97% (4/67); all n P < 0.05]. The incidence of CNS symptoms of patients in cachexia and refractory cachexia stage was higher than that of patients in pre-cachexia stage [32.14% (9/28), 48.00% (12/25) vs. 12.90% (4/31), n P 0.05).n Conclusions:The cancer pain degree of patients in cachexia and refractory cachexia stage is higher than that of patients in pre-cachexia stage. The occurrence of CNS symptoms in patients can be affected by the stages of cachexia and it is not related with the dose of oxycodone.